Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.

Flores-Montero J, de Tute R, Paiva B, Perez JJ, Böttcher S, Wind H, Sanoja L, Puig N, Lecrevisse Q, Vidriales MB, van Dongen JJ, Orfao A.

Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. doi: 10.1002/cyto.b.21265. Epub 2015 Jul 31. Review.

2.

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.

Stetler-Stevenson M, Paiva B, Stoolman L, Lin P, Jorgensen JL, Orfao A, Van Dongen J, Rawstron AC.

Cytometry B Clin Cytom. 2016 Jan;90(1):26-30. doi: 10.1002/cyto.b.21249. Epub 2015 Jul 6.

3.

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.

Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B.

Cytometry B Clin Cytom. 2016 Jan;90(1):31-9. doi: 10.1002/cyto.b.21228. Epub 2015 Jun 2.

4.

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.

Pojero F, Flores-Montero J, Sanoja L, Pérez JJ, Puig N, Paiva B, Bottcher S, van Dongen JJ, Orfao A; EuroFlow group.

Cytometry B Clin Cytom. 2016 Jan;90(1):91-100. doi: 10.1002/cyto.b.21269. Epub 2015 Jul 31.

5.

Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.

Muccio VE, Saraci E, Gilestro M, Gattei V, Zucchetto A, Astolfi M, Ruggeri M, Marzanati E, Passera R, Palumbo A, Boccadoro M, Omedè P.

Cytometry B Clin Cytom. 2016 Jan;90(1):81-90. doi: 10.1002/cyto.b.21279. Epub 2015 Sep 23.

6.

[Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].

Wang YZ, Lu J, Hao L, Chang Y, He LL, Huang XJ, Liu YR.

Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):272-278. doi: 10.3760/cma.j.issn.0253-2727.2017.04.003. Chinese.

PMID:
28468086
7.

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, Kovarova L, Lioznov M, Mateo G, Morilla R, Mylin AK, Omedé P, Pellat-Deceunynck C, Perez Andres M, Petrucci M, Ruggeri M, Rymkiewicz G, Schmitz A, Schreder M, Seynaeve C, Spacek M, de Tute RM, Van Valckenborgh E, Weston-Bell N, Owen RG, San Miguel JF, Sonneveld P, Johnsen HE; European Myeloma Network.

Haematologica. 2008 Mar;93(3):431-8. doi: 10.3324/haematol.11080. Epub 2008 Feb 11.

8.

Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.

Oldaker TA, Wallace PK, Barnett D.

Cytometry B Clin Cytom. 2016 Jan;90(1):40-6. doi: 10.1002/cyto.b.21276. Epub 2015 Sep 4.

9.

Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

10.

Assessment of minimal residual disease in myeloma and the need for a consensus approach.

Rawstron AC, Paiva B, Stetler-Stevenson M.

Cytometry B Clin Cytom. 2016 Jan;90(1):21-5. doi: 10.1002/cyto.b.21272. Epub 2015 Sep 23.

11.

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.

Rawstron AC, de Tute RM, Haughton J, Owen RG.

Cytometry B Clin Cytom. 2016 Jan;90(1):54-60. doi: 10.1002/cyto.b.21271. Epub 2015 Dec 21. Review.

12.

Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.

van Velzen JF, van den Blink D, Bloem AC.

Cytometry B Clin Cytom. 2013 Jan-Feb;84(1):30-2. doi: 10.1002/cyto.b.21044. Epub 2012 Sep 27.

13.

Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.

Gupta R, Bhaskar A, Kumar L, Sharma A, Jain P.

Am J Clin Pathol. 2009 Nov;132(5):728-32. doi: 10.1309/AJCP1GYI7EHQYUYK.

PMID:
19846814
14.

Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.

Liu D, Lin P, Hu Y, Zhou Y, Tang G, Powers L, Medeiros LJ, Jorgensen JL, Wang SA.

J Clin Pathol. 2012 Sep;65(9):823-9. doi: 10.1136/jclinpath-2012-200881. Epub 2012 Jun 8.

PMID:
22685235
15.

Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry.

Wood BL.

Cytometry B Clin Cytom. 2016 Jan;90(1):47-53. doi: 10.1002/cyto.b.21239. Epub 2015 May 29. Review.

17.

Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

Ocqueteau M, Orfao A, Almeida J, Bladé J, González M, García-Sanz R, López-Berges C, Moro MJ, Hernández J, Escribano L, Caballero D, Rozman M, San Miguel JF.

Am J Pathol. 1998 Jun;152(6):1655-65.

19.

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.

Pojero F, Casuccio A, Parrino MF, Cardinale G, Colonna Romano G, Caruso C, Gervasi F.

Cytometry B Clin Cytom. 2015 May-Jun;88(3):165-82. doi: 10.1002/cyto.b.21218. Epub 2015 Feb 3.

20.

Six color flow cytometry detects plasma cells expressing aberrant immunophenotype in bone marrow of healthy donors.

Peceliunas V, Janiulioniene A, Matuzeviciene R, Griskevicius L.

Cytometry B Clin Cytom. 2011 Sep;80(5):318-23. doi: 10.1002/cyto.b.20601. Epub 2011 Jun 1.

Supplemental Content

Support Center